BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish research published today. The patients with lung cancer who received an ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

As psychedelics gain traction as potential treatments for mental health disorders, an international study stands to improve the rigor and reliability of clinical research.

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Discover breakthrough medications that effectively treat nerve pain. Learn about prescription drugs, over-the-counter options ...

Following these outcomes, Sun Pharma has decided to discontinue further clinical trials of SCD-044 and has no plans for its ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.